26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC)
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 14 Jan 2019 Planned End Date changed from 13 Sep 2020 to 17 Sep 2020.
- 14 Jan 2019 Planned primary completion date changed from 13 Sep 2020 to 17 Sep 2020.
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.